.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AB05_Enoxaparin.Enoxaparin

Information

Enoxaparin is a low molecular weight heparin (LMWH) used primarily for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes. It works by inhibiting factor Xa and is widely approved and used in clinical practice for anticoagulation.

Pharmacokinetics

Pharmacokinetics in healthy adult subjects following subcutaneous injection.

References

1. Moffett, BS, et al., & Yee, D (2018). Population Pharmacokinetics of Enoxaparin in Pediatric Patients. The Annals of pharmacotherapy 52(2) 140–146. DOI:10.1177/1060028017734234 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28962537

2. Carreño, FO, et al., & Gonzalez, D (2024). Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population. Clinical pharmacokinetics 63(7) 999–1014. DOI:10.1007/s40262-024-01388-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/38955947

3. Frum, J, et al., & Thomason, J (2022). Anticoagulant profile of subcutaneous enoxaparin in healthy dogs. Journal of veterinary pharmacology and therapeutics 45(1) 34–45. DOI:10.1111/jvp.13015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34622463

Revisions

• 06/2025 initial generated model